Exicure Inc. (XCUR) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Exicure Inc. (XCUR) dropped -8.04% to $0.93, trading at 2% of its 52-week range ($0.88 – $9.48). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 16.1% to $0.92 during Thursday's after-market session. The company's market cap stands at $2.2 million. CareDx (NASDAQ:CDNA) stock rose 15.0% to $82.25.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on XCUR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for XCUR. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Exicure Inc. (XCUR) ranks #831 by composite RQD confidence (35/100, grade D-) and #927 by equity capitalization ($6.1M). Within this direct 5-issuer industry benchmark cohort, XCUR leads on earnings valuation at N/A trailing P/E, while XCUR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ALZN currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with XCUR at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| XCUR
ACTIVE
Exicure Inc. | D- | 35/100 | — | — | -35.0% | -8.04% | $6.1M | Benchmark Subject |
| APRE Aprea Therapeutics Inc. | D- | 42/100 | — | — | -35.0% | -8.22% | $6.2M | /apre-vs-xcur → |
| ACXP Acurx Pharmaceuticals Inc. | D- | 39/100 | — | — | -35.0% | 0.00% | $5.9M | /acxp-vs-xcur → |
| FBLG FibroBiologics Inc. | D- | 40/100 | — | — | -35.0% | -3.99% | $6.3M | /fblg-vs-xcur → |
| ALZN Alzamend Neuro Inc. | D | 47/100 | — | — | -35.0% | +2.52% | $5.9M | /alzn-vs-xcur → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Exicure Inc. (XCUR) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $500.0K ) , GAAP net income of -$4.9M, operating cash flow of -$8.6M, and free cash flow of -$8.6M (-194.0% YoY). On the balance sheet, XCUR closed FY2025 with $14.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$4.9M | -$8.6M | -$8.6M | $14.0M | — |
| FY2024 (FY) | 2024-12-31 | $500.0K | -$9.7M | -$2.9M | -$2.9M | $15.1M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$16.9M | -$10.4M | -$10.4M | — | — |
As of 2026-11-01, Exicure Inc. (NASDAQ: XCUR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.93 (-8.04% 1D, market cap $6.1M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, XCUR ranks #831 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XCUR carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, APRE (Aprea Therapeutics Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $6.2M) and ACXP (Acurx Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $5.9M). Among the 5-stock peer group, XCUR leads on earnings multiple (N/A) while XCUR leads on capital efficiency (-35.0% ROIC).
Per XCUR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001698530), Exicure Inc. generated $0 in revenue (-100.0% YoY), -$4.9M in net income, and -$8.6M in free cash flow against $14.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
XCUR last traded at $0.93 (-8.04% on volume of 41,443 shares), positioning the stock -21.85% below its 50-day simple moving average ($1.19) and -65.81% below its 200-day simple moving average ($2.72). Across its 52-week range of $0.88 to $9.48, XCUR sits at the 0.6% percentile with a 14-day RSI of 43.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.05).
Why XCUR Stock dropped -8.04% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.